Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
GHRP-6 (growth hormone releasing peptide 6) is the first synthetic GHRP ever developed and the foundational compound of the entire GHRP class. It was first characterized by Dr. Cyril Bowers and colleagues at Tulane University in the 1980s, establishing the existence of a novel class of growth hormone secretagogues acting through what would later be identified as the growth hormone secretagogue receptor (GHS-R1a), the receptor for the endogenous "hunger hormone" ghrelin (discovered in 1999, after GHRP-6).
GHRP-6 occupies an unusual position in the GH-axis space. Within the GHRP family, it has the least selective profile, producing the most prominent appetite stimulation, the most cortisol/prolactin elevation, and the most general "ghrelin-like" effects of any GHRP. This made it the GHRP that newer compounds (GHRP-2, then ipamorelin) were specifically designed to improve upon.
However, GHRP-6's pharmacological breadth has driven a distinct line of clinical research: cardioprotective and cytoprotective applications, particularly extensive work by Cuban research groups (Centro de Ingeniería Genética y Biotecnología, CIGB) demonstrating tissue-protective effects across multiple organ systems. The compound's primary scientific interest in 2026 is more in cytoprotective/cardioprotective applications than in GH stimulation per se.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Intravenous GHRP-6 | Bi-exponential; ~15–60 minutes |
| Subcutaneous GHRP-6 | Variable; ~30–60 minutes |
What it does
Main effects
- First synthetic GHRP: foundational compound of the entire GHRP class; established the existence of synthetic GH secretagogues acting through the receptor later identified as GHS-R1a (ghrelin receptor)
- Dual receptor binding: GHS-R1a + CD36. The CD36 binding is particularly important for cardioprotective and cytoprotective effects, distinguishing GHRP-6 from purely GHS-R1a-selective compounds like ipamorelin
- Most prominent appetite stimulation of any GHRP: users experience profound hunger within 20–30 minutes of injection; mediated by ghrelin-like signaling in hypothalamus; desired for cachexia/anorexia indications but undesired for body composition or weight loss goals
- GH release with pulsatile pattern: same fundamental GH-stimulating mechanism as ipamorelin and GHRP-2
- Substantial cardioprotective research from Cuban groups (CIGB): animal studies demonstrate ischemia/reperfusion protection across multiple organs (heart, small bowel, liver, kidneys), antioxidant effects, anti-fibrotic effects (PPAR-gamma upregulation), anti-inflammatory effects (NF-κB pathway modulation), inotropic effects at certain doses, protection against doxorubicin-induced cardiotoxicity
- Phase 1/2 ischemic stroke trial (PMC 11024445): EGF + GHRP-6 combination in 36 acute ischemic stroke patients (Cuba 2017–2018); safety established, favorable neurological/functional evolution at 90 and 180 days, higher 6-month survival; supports Phase 3 advancement
- Post-MI ventricular remodeling protection (PMC 13029777): recent rat model demonstrating improved LV systolic function
- Separate receptor pathway from the GHRH analogs: GHRP-6 acts at GHS-R1a while the GHRH analogs act at the GHRH receptor, both on the same pituitary somatotrophs
What to watch for
Common side effects
- Profound appetite stimulation: defining tolerability feature; rapid onset (20–30 min); "ravenous" hunger; problematic for body composition goals
- Highest cortisol elevation of the major GHRPs: significantly more than ipamorelin or GHRP-2 at comparable GH-releasing doses; clinical implications include weight gain with chronic use (separate from appetite-driven gain), mood effects (anxiety, mood lability), glucose dysregulation, immunosuppression, possible bone density effects long-term, adrenal axis effects
- Significant prolactin elevation: more prominent than other GHRPs; possible galactorrhea, gynecomastia in men, sexual dysfunction, fertility effects
- Injection site reactions (pain, redness, swelling): mild
- Mild constitutional symptoms (flushing, headache, drowsiness, lethargy)
- Insulin resistance with chronic use: combined GH + cortisol effects; more significant than ipamorelin
- IGF-1 elevation with chronic use: monitoring recommended
- Variable cardiovascular effects: largely beneficial in research contexts; possible inotropic effects at certain doses; no significant adverse cardiovascular signal in trials
- No regulatory approval anywhere as therapeutic, unlike GHRP-2 (Japanese diagnostic approval)
- FDA warning letters issued regarding marketing for human administration
- Newer GHRPs (ipamorelin, GHRP-2) are pharmacologically improved for typical GH-axis use. GHRP-6's primary current scientific interest is in cardioprotective/cytoprotective applications, not GH stimulation
- Quality concerns for research chemical supply (identity, concentration, sterility)
- WADA-prohibited under category S2
Key facts
Key facts worth knowing
- GHRP-6 is a synthetic hexapeptide with sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (MW 872.44 Da). It was the first GHRP characterized (Bowers et al. 1980s) and established the entire field of synthetic GH secretagogues that includes GHRP-2, hexarelin, and ipamorelin.
- Mechanism is dual receptor binding: GHRP-6 binds both GHS-R1a (ghrelin receptor) and CD36 receptor. The CD36 binding is particularly important for cardioprotective and cytoprotective effects, distinguishing GHRP-6 from purely GHS-R1a-selective compounds like ipamorelin.
- Most prominent appetite stimulation of any GHRP. Users experience profound hunger within 20–30 minutes of injection. This is desired for cachexia/anorexia indications but undesired for body composition or weight loss goals.
- Highest cortisol elevation of the major GHRPs. Significantly more cortisol stimulation than ipamorelin or GHRP-2 at comparable GH-releasing doses. This is the primary tolerability limitation. Significant prolactin elevation: More prominent than other GHRPs.
- No national regulatory approval for any indication. Unlike GHRP-2 (approved in Japan for diagnostic use), GHRP-6 has not received approval anywhere.
- Substantial cardioprotective research from Cuban groups: The Centro de Ingeniería Genética y Biotecnología (CIGB) has pursued GHRP-6 development for ischemia/reperfusion injury, myocardial infarction protection, and acute ischemic stroke. A Phase 1/2 clinical trial in acute ischemic stroke combined GHRP-6 with epidermal growth factor (EGF) and demonstrated safety and possible benefit, supporting Phase 3 advancement. PMC: 11024445
- Doxorubicin cardiotoxicity prevention: Animal study (PMC 11169835) demonstrating that GHRP-6 prevented doxorubicin-induced heart failure and multi-organ damage in rats. Potential application: cardioprotection during chemotherapy. PMC: 11169835
- Pharmacokinetics characterized in humans: A study in nine male healthy volunteers established bi-exponential disposition with intravenous bolus of 100–400 mcg/kg. Mechanism interest extends beyond GH: The cardioprotective, anti-inflammatory, and cytoprotective effects via CD36 and GHS-R1a have generated substantial research interest independent of GH effects.
- WADA Prohibited under category S2.
Legal status
Legal status
No FDA approval. No regulatory approval anywhere as therapeutic. Cuban clinical development continues for cardioprotective indications. Available through unregulated sources and some compounding pharmacies (with FDA enforcement actions documented). Not a controlled substance. WADA-prohibited under category S2.